fb tracking

Comments Submitted to the CMS Regarding the National Coverage Determination Analysis for Aducanumab Treatment of Alzheimer’s Disease

View as PDF

Public Citizen urged the Centers for Medicare and Medicaid Services (CMS) to issue a national coverage determination that excludes aducanumab from coverage under the Medicare program because there is a lack of scientific evidence that aducanumab provides any meaningful clinical benefit in terms of cognitive function outcomes in Alzheimer’s disease patients and the drug thus is not reasonable and necessary for treatment of such patients.

See Public Citizen’s other work on aducanumab.